X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.fiercebiotech.com/biotech/new-fda-guidelines-consider-amyloid-reduction-reasonably-likely-predict-clinical-benefit
https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-discontinue-development-older-alzheimers-drug-aduhelm-2024-01-31/
https://www.fiercepharma.com/pharma/biogen-scores-win-massachusetts-judge-dismisses-investor-lawsuit
https://endpts.com/va-to-cover-eisais-new-alzheimers-drug-after-declining-to-cover-aduhelm/
https://www.fiercebiotech.com/biotech/dunn-fda-head-neuroscience-unit-depart
https://endpts.com/fda-adds-warning-of-larger-areas-of-bleeding-in-brain-to-biogens-aduhelm-label/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178
https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-files-approval-alzheimers-drug-europe-2023-01-10/
https://www.fiercepharma.com/marketing/eisai-taps-its-native-tongue-beauty-and-health-it-names-freshly-approved-alzheimers-drug
https://endpts.com/congressional-inquiry-into-highly-atypical-fda-biogen-ties-ends-with-damning-report-no-repercussions/
https://www.fiercepharma.com/pharma/biogen-fdas-inappropriate-aduhelm-coordination-detailed-blistering-congressional-report
https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-biogens-new-alzheimers-drug-should-be-priced-below-aduhelm-report-2022-12-23/
https://endpts.com/icer-on-alzheimers-lecanemab-should-be-priced-lower-than-aduhelm/
https://endpts.com/ahead-of-lecanemab-decision-alzheimers-groups-petition-cms-to-reverse-coverage-policy/
https://www.biopharmadive.com/news/lilly-donanemab-amyloid-clearance-aduhelm-ctad/637721/
https://www.fiercebiotech.com/biotech/winner-crowned-head-head-battle-between-lilly-and-biogens-alzheimers-drugs
https://www.europeanpharmaceuticalreview.com/news/176012/first-virtual-clinical-trial-examines-two-promising-alzheimers-drugs/
https://pharmaphorum.com/news/fda-delays-decision-on-biogens-als-hope-tofersen/
https://www.prnewswire.com/news-releases/shareholder-alert-biogen-inc-biib-officers-and-directors-under-investigation-for-possible-false-statements-about-aduhelm-301648375.html#:~:text=SAN%20FRANCISCO%2C%20Oct.%2013%2C,an%20alleged%20illegal%20kickback%20scheme
https://www.fiercepharma.com/pharma/eisai-inaugurates-new-us-hq-closely-watched-fda-alzheimers-decision-draws-near
https://www.statnews.com/2022/08/10/amid-aduhelm-woes-biogen-moves-to-pare-back-office-space/
https://www.fiercepharma.com/pharma/biogen-deflects-claims-it-misled-shareholders-about-aduhelms-success
https://endpts.com/for-accounting-purposes-biogen-says-its-223m-inventory-of-aduhelm-is-basically-worthless/
https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q2-2022/
https://endpts.com/biogen-yanks-its-aduhelm-application-in-canada-days-after-celebrating-the-drugs-1-year-anniversary-in-the-us/
https://endpts.com/medicare-doesnt-reduce-its-2022-premium-hike-even-as-use-of-biogens-alzheimers-drug-is-sharply-curtailed/
https://www.fiercepharma.com/marketing/neurologists-turning-their-backs-aduhelm-trials-cms-decision-has-not-killed-hope-all-anti
https://www.fiercebiotech.com/biotech/eisai-completes-filing-biogen-partnered-aduhelm-follow-hoping-regain-credibility-and-trust
https://www.bloombergquint.com/business/biogen-ceo-to-leave-after-alzheimer-s-drug-fails-get-covered
https://www.fiercepharma.com/pharma/new-biogen-ceos-most-prized-expertise-dealmaking-experience-say-investors
https://www.fiercebiotech.com/biotech/biogen-shoves-aduhelm-side-its-time-lecanemab
https://www.investors.com/news/technology/biogen-stock-biogen-earnings-q1-2022/
https://www.statnews.com/2022/04/29/biogen-ceo-michel-vounatsos-bonus-cut-aduhelm/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178
https://www.fiercepharma.com/pharma/aduhelm-loses-another-potential-sales-avenue-biogen-pulls-marketing-application-europe
https://health.economictimes.indiatimes.com/news/pharma/the-fda-approved-a-new-drug-to-treat-alzheimers-but-medicare-wont-always-pay-for-it-a-doctor-explains-what-researchers-know-about-biogens-aduhelm/90909041
https://www.fiercepharma.com/pharma/cms-sticks-its-guns-will-limit-coverage-biogens-aduhelm-clinical-trials
https://endpts.com/about-as-true-as-saying-the-earth-is-flat-alzheimers-expert-picks-apart-biogens-aduhelm-manuscript/
https://www.fiercepharma.com/marketing/department-health-and-human-services-investigating-how-consumers-are-marketed-accelerated
https://www.globenewswire.com/news-release/2022/03/30/2412737/0/en/Biogen-Submits-Final-Protocol-for-ADUHELM-aducanumab-avwa-Phase-4-ENVISION-Trial-to-FDA.html
https://www.globenewswire.com/news-release/2022/03/16/2404260/0/en/Long-Term-Phase-3-Data-Show-ADUHELM-Continues-to-Reduce-Underlying-Pathologies-of-Alzheimer-s-Disease-in-Patients-Treated-for-More-Than-Two-Years.html
https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-receive-royalties-instead-profits-alzheimers-drug-aduhelm-2022-03-15/
https://www.biopharmadive.com/news/biogen-layoffs-jobs-aduhelm/619768/
https://www.fiercepharma.com/pharma/death-3-more-patients-biogen-s-aduhelm-fuel-more-concern-about-drug-s-safety-though-no-link
https://www.fiercepharma.com/pharma/biogen-eisai-strike-back-against-cms-stifling-aduhelm-coverage-proposal
https://endpts.com/biogen-slams-coverage-proposal-for-amyloid-targeted-alzheimers-drugs-in-31-page-comment/
https://www.healthcareafrica.info/2022/02/07/lilly-slacks-off-fda-submission-of-alzheimers-drug-after-cms-decision-on-aduhelm/
https://www.healthcareafrica.info/2022/02/07/more-federal-regulators-launch-probe-into-biogens-aduhelm/
https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-says-us-ftc-probing-alzheimers-disease-drug-2022-02-04/
https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-profit-falls-18-higher-costs-2022-02-03/
Market Place
Share 
